- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02986880
Effect of Type-A Botulinum Toxin in the Post-radiosurgical Neck Contractures
May 24, 2017 updated by: Hopital Foch
A Dose-response, Randomized, Double-blind Study to Evaluate the Effect of Type-A Botulinum Toxin in the Post-radiosurgical Neck Contractures
The main objective of the study is to estimate the efficiency and to determine the optimal dose of Botulinum toxin A, administered by intramuscular way in cervical spasms after radiotherapy, as well as the optimal sites for these injections.
The concerned muscular groups are the sternocleidomastoid (SCM), the trapezius muscle and the splenius capitis.
Study Overview
Status
Completed
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
14
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Suresnes, France, 92150
- Hopital Foch
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 75 years (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Patients from 18 to 75 years old;
- malignant Tumor of aerodigestive ways, in forgiveness;
- Treatment containing the external radiotherapy ended since > 6 months
- Life expectancy > 6 months;
- patient complaining from cervical spasms with functional disability;
- Negative Pregnancy test;
- Women under effective contraception;
- Patients benefiting from a national insurance scheme;
- Patient having given a written consent.
Exclusion Criteria:
- Cervico-facial Surgery with reconstruction by pedicled flap
- Implantable Chamber with catheter in the internal jugular vein near the spasm;
- Muscular, neurological Pathology or malformative pulling a disorder of perception of the pain, an amyotrophy, a muscular weakness affecting the cervical axis or the upper limbs;
- Disorder generalized by the muscular activity (ex myasthenia);
- Cervical osseous or muscular Pathology pulling pains and disability before the beginning of the treatment (cervical degenerative osteoarthritis diagnosed to the cervical radiography, the slipped disc);
- Previous cervical injection of botulinum toxin ;
- Local Infection at the level of one of the sites proposed for injection;
- Histories of epilepsy;
- Patients presenting a hypersensitivity to the botulinum neurotoxin A or in one of its excipients;
- Patients under anticoagulation therapy, Under antibiotic treatment by aminoglycosides or amino 4 quinoline, under myorelaxant treatment or that must undergo an intervention with curarisation;
- Patients for whom a surgical operation is planned in the zone interested in the treatment
- Pregnant or breast-feeding Women;
- Patients for whom questionnaires will not be assessable (handicaps of communication, patient not speaking French, etc.).
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: TRIPLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Group D1
Patients receiving the toxin in SCM and the placebo in trapezius muscle and splenius capitis.
Patients receiving the dose of 30 units (U) at injection point, totalling 120 U.
|
|
EXPERIMENTAL: Group D2
Patients receiving the toxin in the SCM and the placebo in the trapezius muscle and the splenius capitis.
Patients receiving the dose of 60 units (U) at injection point, totalling 240 U.
|
|
EXPERIMENTAL: Group D3
Patients receiving the toxin in the SCM and the placebo in the trapezius muscle and the splenius capitis.
Patients receiving the dose of 100 units (U) at injection point, totalling 400 U.
|
|
EXPERIMENTAL: Group A1
Patients receiving the toxin in trapezius muscle and splenius capitis and the placebo in SCM .
Patients receiving the dose of 30 units (U) at injection point, totalling 180 U.
|
|
EXPERIMENTAL: Group A2
Patients receiving the toxin in trapezius muscle and splenius capitis and the placebo in SCM .
Patients receiving the dose of 60 units (U) at injection point, totalling 360 U.
|
|
EXPERIMENTAL: Group A3
Patients receiving the toxin in trapezius muscle and splenius capitis and the placebo in SCM .
Patients receiving the dose of 100 units (U) at injection point, totalling 600 U.
|
|
EXPERIMENTAL: Group F1
Patients receiving the toxin in the third muscles groups.
Patients receiving the dose of 30 units (U) at injection point, totalling 300 U.
|
|
EXPERIMENTAL: Group F2
Patients receiving the toxin in the third muscles groups.
Patients receiving the dose of 60 units (U) at injection point, totalling 600 U.
|
|
EXPERIMENTAL: Group F3
Patients receiving the toxin in the third muscles groups.
Patients receiving the dose of 100 units (U) at injection point, totalling 1000 U.
|
|
PLACEBO_COMPARATOR: Group P
Patients receiving placebo in the third muscles groups
|
Injection of sodium chloride (NaCl) 9/1000
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Cervical mobility degree
Time Frame: 6 months
|
6 months
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Quality of Life Questionnaire Module for Head and Neck Cancer (QLQ-H&N35)
Time Frame: 6 months
|
6 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Christine Bach, Hopital Foch
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
June 1, 2011
Primary Completion (ACTUAL)
January 10, 2014
Study Completion (ACTUAL)
January 10, 2014
Study Registration Dates
First Submitted
December 6, 2016
First Submitted That Met QC Criteria
December 6, 2016
First Posted (ESTIMATE)
December 8, 2016
Study Record Updates
Last Update Posted (ACTUAL)
May 25, 2017
Last Update Submitted That Met QC Criteria
May 24, 2017
Last Verified
May 1, 2017
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Neurologic Manifestations
- Joint Diseases
- Musculoskeletal Diseases
- Muscular Diseases
- Dyskinesias
- Dystonia
- Torticollis
- Contracture
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Peripheral Nervous System Agents
- Cholinergic Agents
- Membrane Transport Modulators
- Acetylcholine Release Inhibitors
- Neuromuscular Agents
- Botulinum Toxins
- Botulinum Toxins, Type A
- abobotulinumtoxinA
Other Study ID Numbers
- 2011/08
- 2011-000889-35 (EUDRACT_NUMBER)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Radiotherapy Side Effect
-
National Cancer Institute, EgyptUnknownRadiotherapy Side EffectEgypt
-
Centre hospitalier de l'Université de Montréal...RecruitingCancer | Radiotherapy Side EffectCanada
-
Centre hospitalier de l'Université de Montréal...RecruitingCancer | Radiotherapy Side EffectCanada
-
Centre Leon BerardRecruitingCancer | Radiotherapy Side EffectFrance
-
Medical University of ViennaRecruiting
-
Centre Francois BaclesseCompletedRadiotherapy Side Effect | Merkel CarcinomaFrance
-
Umeå UniversityCompletedPediatric ALL | Radiotherapy Side Effect
-
Latin American Cooperative Oncology GroupRecruitingRadiotherapy Side EffectBrazil
-
Samsung Medical CenterRecruitingRadiotherapy Side EffectKorea, Republic of
-
The Christie NHS Foundation TrustActive, not recruitingGynecologic Cancer | Radiotherapy Side Effect | FractureUnited Kingdom
Clinical Trials on Botulinum toxin A
-
AllerganTerminatedOveractive BladderSerbia, Turkey, Greece, Egypt, Lebanon, India
-
Walter Reed Army Medical CenterUnknown
-
YangHuiUnknown
-
Daewoong Pharmaceutical Co. LTD.Completed
-
Mentor Worldwide, LLCSynteract, Inc.CompletedGlabellar RhytidesUnited States
-
AllerganCompletedOveractive BladderPortugal, South Africa, Netherlands, Canada, Singapore, Brazil, United States, Taiwan, Italy, United Kingdom, France, Spain
-
AllerganCompletedOveractive BladderUnited Kingdom, Belgium, New Zealand, France, Russian Federation, Czech Republic, United States, Germany, Austria, Poland, Slovakia, Ukraine, Canada, Australia
-
Mentor Worldwide, LLCSynteract, Inc.CompletedGlabellar Rhytides | Frown Lines Between the EyebrowsUnited States
-
OHSU Knight Cancer InstituteOregon Health and Science UniversityRecruitingPancreatic CarcinomaUnited States
-
Mentor Worldwide, LLCQuintiles, Inc.CompletedGlabellar RhytidesUnited States